Despite the absence of empirical evidence, there is a popular perception that brachytherapy results in less impairment of health-related quality of life. This study compared general and disease-speci®c health-related quality of life in men who had undergone either brachytherapy (with and without pre-treatment XRT) or radical prostatectomy, and in healthy age-matched controls.
Method
We surveyed all patients with clinical T2 or less prostate cancer who had undergone interstitial seed brachytherapy at UCLA during the previous 3±17 months. Each was paired with two randomly selected, temporally matched radical prostatectomy patients. Healthy, age-matched controls were drawn from the literature. Surgery and brachytherapy procedures were performed by boardcerti®ed faculty physicians. Quality of life outcome measures included the RAND 36-item Health Survey (SF-36), the UCLA Prostate Cancer Index (PCI) and the American Urological Association Symptom Index (AUASI). Clinical variables were collected by chart abstraction.
Results
Response rates were 86% (n 50) for the brachytherapy patients and 74% (n 76) for the radical prostatectomy patients. In the general health-related quality of life domains, brachytherapy and radical prostatectomy patients had similar scores to each other and to the healthy, age-matched controls. PCI urinary function (leakage) was worst in radical prostatectomy patients, better in brachytherapy patients and best in the healthy controls. AUASI scores (irritative and obstructive symptoms) were worse in the brachytherapy patients than in the radical prostatectomy or control patients. PCI bowel function was worse in the brachytherapy patients than in the controls. PCI sexual function and bother were equivalent in the radical prostatectomy and brachytherapy groups, both of which were worse than the control group. The PCI urinary domains improved over time among the radical prostatectomy and brachytherapy patients. AUASI scores were stable following radical prostatectomy, but improved over time in the brachytherapy patients. Brachytherapy patients who received pre-treatment XRT had worse general and disease-speci®c health-related quality of life and AUASI scores than those who did not receive XRT. Sildena®l appeared to have little effect in the radical prostatectomy patients. However, brachytherapy patients not receiving hormonal ablation or XRT who took sildena®l had better sexual function and bother scores than those patients who did not.
Conclusion
General health-related quality of life did not differ greatly between the three groups, but there were variations in disease-speci®c (urinary, bowel and sexual) health-related quality of life. Radical prostatectomy patients had the worst urinary function (leakage), but brachytherapy patients were also signi®cantly worse than the controls. Control subjects had less urinary bother than the radical prostatectomy or brachytherapy patients, but brachytherapy patients had more irritative and obstructive symptoms than the radical prostatectomy patients or controls. Over time, brachytherapy improved in general healthrelated quality of life domains, whereas the radical prostatectomy patients remained stable. Urinary leakage scores improved in both surgery and brachytherapy patients over time, while irritative and obstructive symptoms improved in the brachytherapy patients. Despite similar age, co-morbidity and time since treatment, brachytherapy patients who received pre-treatment XRT performed worse in all quality-of-life domains than those who did not receive pre-treatment XRT. Finally, sildena®l may be more effective in brachytherapy patients than in patients who have undergone radical prostatectomy.
The conclusions of this study are limited by its retrospective, cross-sectional design. However, the study provides important insights into the quality of life of patients who have undergone brachytherapy for early-stage prostate cancer. At an average of 7.5 months after treatment, their general health-related quality of life was similar to that of the controls, although they had more urinary, bowel and sexual problems. These appear to improve during the ®rst year after treatment. In addition, their erectile dysfunction may be effectively managed with sildena®l. Much of the impairment in disease-speci®c health-related quality of life among brachytherapy patients may be attributed to the use of pre-treatment XRT. Nonetheless, brachytherapy with or without XRT does affect health-related quality of life, and this must be clearly explained to patients, many of whom may expect a treatment free of side-effects. All quality of life scales may range from 0 to 100, with higher scores representing better outcomes, except the AUA Symptom Index, which may range from 0 to 35, with higher scores representing worse outcomes.
